Wockhardt Ltd. News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Wockhardt Ltd. authored by Axis Direct and published by - Trendlyne research reports.
Item: Wockhardt Ltd.
Rating: 5
Author: Axis Direct

Keep track of all breaking news and updates on Wockhardt Ltd. from all sources in a single place.

Load latest

Wockhardt Ltd.

11 Jul 2025

1470.20

1.47%

Company Update

Wockhardt Ltd - 532300 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Please find enclosed Press Release "Wockhardt Initiates Strategic Realignment of US Operations to Focus on Innovative Portfolio"

pdf

Wockhardt Ltd.

08 Jul 2025

1470.20

1.47%

Axis Punch:Wockhardt

Buy: Wockhardt Ltd.

Axis Direct

We recommend a BUY rating on the stock, with a target price of Rs 1,870/share reflecting 10% upside potential from the CMP.

Wockhardt Ltd.'s price crossed above 200Day SMA today

Wockhardt Ltd.

26 Jun 2025, 01:14PM

1470.20

1.47%

SAST

Wockhardt Ltd - 532300 - Closure of Trading Window

BSE India

This is to inform you that pursuant to Company''s ''Code of Conduct for regulating, monitoring, and reporting trading by designated persons'', the Trading Window for dealing in equity shares of the Company will be closed from 1st July, 2025 until 48 hours after the declaration of unaudited financial results of the company for the quarter ended 30th June, 2025.

pdf

Wockhardt Ltd.

11 Jun 2025

1470.20

1.47%

Earnings Call

Wockhardt Ltd - 532300 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

Pursuant to Regulation 30 of Securities and Exchange Board of India (LODR) Regulations, 2015, as amended and in continuation to our letter bearing reference number Ref no: WOCK/SEC/SE/2025-26/012 dated 2nd June, 2025, please find enclosed the transcript of the presentation made in the Investor meeting held on Thursday, 5th June, 2025, for your information and records.

pdf

Wockhardt Ltd.

05 Jun 2025

1470.20

1.47%

Wockhardt's New Antibiotic Zaynich Targets $7-Billion US, Europe Market

NDTV Profit

The company plans to file for USFDA approval in the second quarter of the current financial year.

Wockhardt Ltd. has an average target of 1870.00 from 1 broker.

Wockhardt files for regulatory approval of novel antibiotic Zaynich

Business Line | 05 Jun 2025

Wockhardt Ltd.

05 Jun 2025

1470.20

1.47%

Investor Presentation

Wockhardt Ltd - 532300 - Announcement under Regulation 30 (LODR)-Investor Presentation

BSE India

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended and in continuation of our letter bearing reference number WOCK/SEC/SE/2025-26/012 dated 2nd June, 2025 please find enclosed herewith a copy of the updated Investor Presentation.

pdf

Wockhardt Ltd.

05 Jun 2025

1470.20

1.47%

Investor Presentation

Wockhardt Ltd - 532300 - Announcement under Regulation 30 (LODR)-Investor Presentation

BSE India

Pursuant to Regulation 30 of SEBI LODR Regulations, 2015, and in continuation to our letter dated 2nd June, 2025, Please find enclosed herewith a copy of Investor Presentation to be made at the Investor Meet scheduled to be held today, i.e. 5th June, 2025.

pdf

Wockhardt Ltd.

04 Jun 2025

1470.20

1.47%

Wockhardt Aims To Regain Rs 5,000-Crore Revenue In Three Years, Says Chairperson Khorakiwala

NDTV Profit

In FY25, the company's revenue stood at Rs 3,012 crore, compared to Rs 2,798 crore in FY24.

Wockhardt Ltd. is trading above its 200 day SMA of 1449.5

Wockhardt Ltd.

02 Jun 2025

1470.20

1.47%

Company Update

Wockhardt Ltd - 532300 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company will hold an Investor meet/call on Thursday, 5th June, 2025 at 11:00 hrs IST through VC and in-person as detailed in the enclosed invite. The meeting/call will be initiated with a presentation by Dr. Murtaza Khorakiwala, Managing Director and will be followed by a Q&A Session in presence of Dr. Habil Khorakiwala, Chairman.

pdf